KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Current Deferred Revenue (2016 - 2022)

Bio-Rad Laboratories (BIO) has disclosed Current Deferred Revenue for 13 consecutive years, with $52.2 million as the latest value for Q4 2022.

  • Quarterly Current Deferred Revenue rose 2.65% to $52.2 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $52.2 million through Dec 2022, up 2.65% year-over-year, with the annual reading at $52.2 million for FY2022, 2.65% up from the prior year.
  • Current Deferred Revenue for Q4 2022 was $52.2 million at Bio-Rad Laboratories, up from $50.9 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $52.2 million in Q4 2022, with the low at $26.9 million in Q4 2018.
  • Average Current Deferred Revenue over 5 years is $43.9 million, with a median of $44.4 million recorded in 2019.
  • The sharpest move saw Current Deferred Revenue skyrocketed 70.03% in 2019, then fell 7.28% in 2020.
  • Over 5 years, Current Deferred Revenue stood at $26.9 million in 2018, then surged by 70.03% to $45.8 million in 2019, then fell by 7.28% to $42.5 million in 2020, then increased by 19.74% to $50.9 million in 2021, then increased by 2.65% to $52.2 million in 2022.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $52.2 million, $50.9 million, and $42.5 million for Q4 2022, Q4 2021, and Q4 2020 respectively.